Related Experiment Video

Updated: Jun 15, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer

Zuo Yunxia1, Cao Jun, Zhu Guanshan

  • 1Department of Medical Oncology, Fudan University Cancer Hospital, Shanghai Medical School, Shanghai 200032, PR China.

BMC Medical Genetics
|February 27, 2010
PubMed
Abstract

Insights

EGFR mutations are rare in Chinese colorectal cancer (CRC) patients, while K-ras mutations are common and linked to poor differentiation. K-ras mutations did not independently affect survival in this cohort.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Epidermal Growth Factor Receptor (EGFR) and Kirsten Rat Sarcoma (K-ras) mutations are key biomarkers for targeted therapies in non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC).
  • Limited data exists on the prevalence and clinical significance of EGFR and K-ras gene mutations in Chinese patients diagnosed with CRC.

Purpose of the Study:

  • To investigate the mutation status of EGFR and K-ras genes in a cohort of Chinese CRC patients.
  • To analyze the correlation between gene mutation status, patient characteristics, and survival outcomes.

Main Methods:

  • Tumor samples from 101 Chinese CRC patients were analyzed for EGFR mutations (exons 18-21) and K-ras mutations (exons 1-2) using polymerase chain reaction and Sanger sequencing.
  • Statistical analysis, including logistic regression, was employed to assess relationships between mutations, patient demographics, and survival.

Main Results:

  • EGFR mutations were infrequent (2.0%), while K-ras mutations were detected in 32.7% of patients, with novel mutations identified in codons 45, 69, and 80.
  • Poor differentiation was significantly associated with K-ras mutations (p=0.04).
  • K-ras mutation status did not emerge as an independent prognostic factor for overall survival or post-metastasis survival.

Conclusions:

  • EGFR mutations are rare in Chinese CRC patients, whereas K-ras mutation frequencies are comparable to European populations.
  • The study identified novel K-ras mutations in codons 45, 69, and 80 within the Chinese population.
  • Poor tumor differentiation is an independent factor associated with K-ras mutations in this CRC cohort.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...